Association between symptom improvement and change of body mass index, lipid profile, and leptin, ghrelin, and cholecystokinin levels during 6-week olanzapine treatment in patients with first-episode psychosis.
Basoglu
Cengiz
C
Oner
Ozgur
O
Ates
Alpay M
AM
Algul
Ayhan
A
Semiz
Umit Basar
UB
Ebrinc
Servet
S
Cetin
Mesut
M
Ozcan
Omer
O
Ipcioglu
Osman Metin
OM
D001569:Benzodiazepines / Q000008:administration & dosage*; D015992:Body Mass Index; D002766:Cholecystokinin / Q000097:blood*; D054439:Ghrelin / Q000097:blood*; D006801:Humans; D020738:Leptin / Q000097:blood*; D008055:Lipids / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000097:blood* / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D054439:Ghrelin; D020738:Leptin; D008055:Lipids; D008077:Lipoproteins, LDL; D014280:Triglycerides; D001569:Benzodiazepines; D002766:Cholecystokinin; D000077152:Olanzapine